- Conditions
- Osteoarthritis, Knee, Osteo Arthritis Knee, Knee Osteoarthritis
- Interventions
- GNSC-001, transient immune-modulation, Placebo
- Genetic · Drug
- Lead sponsor
- Genascence Corporation
- Industry
- Eligibility
- 40 Years to 75 Years
- Enrollment
- 67 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2029
- U.S. locations
- 9
- States / cities
- Mobile, Alabama • La Mesa, California • San Diego, California + 6 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2025 · Synced May 22, 2026, 4:49 AM EDT